Reports related to this article:
Project(s): View 1 related project in PECWeb
Plant(s): View 1 related plant in PECWeb
Released April 02, 2021 | SUGAR LAND
en
Genentech, the first publicly owned biotechnology company, recently completed an individualized neoantigen-specific immunotherapy (iNeST) facility on its campus in Hillsboro, Oregon. Using proprietary algorithms, the iNeST process involves DNA extraction from an individual patient's tumor cells and sequences, according to the company.
"By comparing the sequences of the patient's tumor mutations with germline DNA from normal cells, tumor mutations are identified," according to Genentech. "Then, using proprietary algorithms that evaluate the immunogenic potential of the tumor mutations in the context of the patient's HLA (human leukocyte antigen) type, the neoantigens most likely to elicit an immune response are selected and incorporated into an iNeST."
The $170 million Hillsboro campus facility was designed by Group Mackenzie and PM Global Group and was built by Turner Construction Company.
See map below.
"By comparing the sequences of the patient's tumor mutations with germline DNA from normal cells, tumor mutations are identified," according to Genentech. "Then, using proprietary algorithms that evaluate the immunogenic potential of the tumor mutations in the context of the patient's HLA (human leukocyte antigen) type, the neoantigens most likely to elicit an immune response are selected and incorporated into an iNeST."
The $170 million Hillsboro campus facility was designed by Group Mackenzie and PM Global Group and was built by Turner Construction Company.
See map below.
